How to Use CJC-1295 No DAC & Ipamorelin for Recovery
Fewer than 30% of athletes who experiment with peptide-based recovery protocols use the compounds at the right dose, timing, and frequency to produce measurable results. The gap isn't pharmacological. It's procedural. CJC-1295 no DAC (without drug affinity complex) and Ipamorelin are both growth hormone secretagogues (GHS), but they work through different mechanisms at the pituitary level. CJC-1295 amplifies the magnitude of each growth hormone pulse, while Ipamorelin increases pulse frequency and preserves the natural circadian rhythm that exogenous growth hormone obliterates. Together, they restore the hormonal environment required for protein synthesis, collagen deposition, and tissue remodelling. Without triggering the insulin resistance, joint oedema, or cortisol elevation seen with synthetic GH administration.
Our team has guided research protocols across multiple performance and recovery contexts. The compounds themselves are straightforward. Reconstitution, dosing, and injection are not the hard part. What matters is the timing relative to training load, sleep architecture, and baseline GH secretion capacity. Most guides treat CJC-1295 and Ipamorelin as interchangeable with GHRP-6 or Hexarelin. They're not. The selectivity profile of Ipamorelin means it doesn't significantly elevate prolactin or cortisol, making it safe for extended use in recovery-focused protocols where those hormonal disruptions compound fatigue rather than resolve it.
How do CJC-1295 no DAC and Ipamorelin accelerate recovery compared to baseline physiology?
CJC-1295 no DAC and Ipamorelin synergistically restore growth hormone pulsatility by acting at complementary pituitary receptors. CJC-1295 increases pulse amplitude by prolonging GHRH (growth hormone-releasing hormone) receptor activation, while Ipamorelin increases pulse frequency through ghrelin receptor (GHS-R1a) stimulation. This dual-action protocol produces 2–5× baseline GH output during nocturnal secretion windows without suppressing endogenous production. The result: faster muscle protein synthesis (MPS) rates, reduced inflammatory cytokine persistence, and improved Stage 3/4 sleep architecture. All of which directly support tissue repair and systemic recovery.
Most people assume growth hormone secretagogues work identically to exogenous GH. They don't. Exogenous GH administration suppresses natural pulsatile secretion entirely and can remain elevated for 8–12 hours post-injection, creating sustained insulin resistance and lipolysis that interferes with glycogen repletion. CJC-1295 no DAC has a half-life of approximately 6–8 days, but it doesn't produce continuous GH elevation. It amplifies your body's natural pulses, which still occur in the 90–180 minute ULTRADIAN rhythm governed by the hypothalamic-pituitary axis. Ipamorelin's half-life is roughly 2 hours, meaning it acts acutely during the administration window and clears rapidly. This article covers the exact dosing schedule that preserves natural GH rhythm, how to reconstitute and administer both peptides without contamination, and what recovery markers to track to confirm the protocol is working.
Step 1: Reconstitute CJC-1295 No DAC and Ipamorelin Using Sterile Technique
Both peptides arrive as lyophilised powder and must be reconstituted with bacteriostatic water before injection. Reconstitution isn't difficult. Contamination is. Every time you puncture the rubber stopper with a needle, you create an entry point for bacteria. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth for up to 28 days post-reconstitution, but it doesn't sterilise the vial if you've already introduced contamination through poor technique.
Use a fresh alcohol swab on the vial stopper before every needle puncture. Not the same swab you used 30 seconds ago. Inject air into the bacteriostatic water vial equal to the volume you're withdrawing to prevent vacuum formation. When adding bacteriostatic water to the peptide vial, inject it slowly down the inside wall of the vial. Not directly onto the lyophilised cake. Direct injection can denature the peptide structure through shear force, reducing bioavailability by 15–25%. Gently swirl the vial in a circular motion. Never shake it. Shaking introduces air bubbles and mechanical stress that fragment peptide chains.
For a standard 5mg vial of CJC-1295 no DAC or Ipamorelin, add 2mL of bacteriostatic water. This produces a concentration of 2.5mg/mL (2,500mcg/mL), making dose calculation straightforward: 0.1mL = 250mcg. Store reconstituted vials at 2–8°C (refrigerator temperature) and use within 28 days. Lyophilised peptides stored at −20°C before reconstitution remain stable for 12–24 months. Once mixed, the 28-day window is non-negotiable.
Step 2: Administer CJC-1295 No DAC and Ipamorelin at Optimal Timing Windows
Timing determines whether this protocol amplifies recovery or simply elevates GH without functional benefit. Growth hormone pulses naturally during deep sleep (Stage 3 and 4 NREM), particularly during the first 90–120 minutes after sleep onset. CJC-1295 and Ipamorelin administered 15–30 minutes before bed synchronise with this endogenous pulse, producing a combined GH spike 3–6× higher than baseline without disrupting cortisol or prolactin.
The recommended dose for recovery-focused protocols: 100–200mcg CJC-1295 no DAC combined with 200–300mcg Ipamorelin, administered subcutaneously in the abdominal region. These compounds can be drawn into the same syringe and injected together. They don't interact negatively. Inject at least two hours after your last meal to avoid blunting the GH response through elevated blood glucose and insulin. Carbohydrate intake within 90 minutes of injection can reduce GH secretion by 40–50% because insulin directly inhibits GHRH release at the hypothalamus.
Frequency depends on training load and recovery deficit. For acute recovery (post-competition, high-volume training blocks), administer nightly for 5–7 consecutive nights, then cycle off for 2–3 days. For maintenance recovery, use 3–4 nights per week on non-consecutive days. Continuous daily use beyond 8–10 weeks may lead to receptor desensitisation, reducing the magnitude of GH response over time. Cycling preserves receptor sensitivity and prevents tolerance.
Step 3: Monitor Recovery Markers to Confirm Protocol Efficacy
Peptide protocols fail when users assume elevated GH automatically equals faster recovery. It doesn't. Growth hormone facilitates recovery by increasing IGF-1 (insulin-like growth factor 1) production in the liver, which mediates most of GH's anabolic effects on muscle and connective tissue. IGF-1 levels peak 8–12 hours after a GH pulse, meaning recovery benefits lag behind administration by at least one sleep cycle.
Track these markers to confirm the protocol is working: subjective sleep quality (deeper, less interrupted sleep within 3–5 nights), reduced delayed-onset muscle soreness (DOMS) duration (recovery from high-eccentric sessions within 36–48 hours instead of 60–72 hours), improved morning grip strength or vertical jump height (neuromuscular recovery), and skin elasticity or minor wound healing speed (collagen synthesis indicator). Quantitative tracking: measure resting heart rate variability (HRV) using a chest-strap monitor. Improved parasympathetic tone (higher HRV) within 7–10 days suggests systemic recovery enhancement.
Blood work can confirm IGF-1 elevation if baseline levels are available. A 20–40% increase in serum IGF-1 within 2–3 weeks of starting the protocol indicates effective GH amplification. IGF-1 reference range: 115–307 ng/mL for adults aged 25–39. Levels below 150 ng/mL suggest suboptimal GH secretion. A strong candidate for secretagogue intervention. Avoid testing IGF-1 within 48 hours of heavy resistance training, as acute exercise transiently elevates IGF-1 independent of peptide use.
CJC-1295 No DAC & Ipamorelin: Protocol Comparison
| Protocol Type | CJC-1295 Dose | Ipamorelin Dose | Injection Frequency | Primary Application | Expected Outcome | Professional Assessment ||—|—|—|—|—|—|| Acute Recovery (Post-Competition) | 200mcg | 300mcg | Nightly for 5–7 days | High training load, competition recovery, injury rehab | 30–50% faster return to baseline performance markers; reduced systemic inflammation | Best for short-term recovery bursts. Not sustainable beyond 10 days without rest || Maintenance Recovery | 100mcg | 200mcg | 3–4 nights/week (non-consecutive) | Ongoing training, chronic fatigue management | Sustained deep-sleep quality; 15–25% reduction in DOMS duration | Ideal for long-term use. Minimises receptor desensitisation || Pre-Sleep Only | 100–150mcg | 200–250mcg | Nightly before bed | Sleep architecture optimisation, CNS recovery | Improved Stage 3/4 sleep; higher morning HRV | Works synergistically with magnesium glycinate and low blue-light exposure || Injury Rehab Focus | 150–200mcg | 250–300mcg | 5 nights/week for 4–6 weeks | Tendon, ligament, or muscle strain recovery | Faster collagen deposition; reduced inflammatory cytokine persistence | Combine with BPC-157 or TB-500 for enhanced tissue repair |
Key Takeaways
CJC-1295 no DAC amplifies growth hormone pulse amplitude, while Ipamorelin increases pulse frequency. Together they restore pulsatile GH secretion suppressed by stress, poor sleep, and aging.
Reconstitute both peptides with bacteriostatic water at 2.5mg/mL concentration, inject slowly down the vial wall to prevent denaturation, and store at 2–8°C for up to 28 days post-mixing.
Administer 100–200mcg CJC-1295 with 200–300mcg Ipamorelin subcutaneously 15–30 minutes before bed, at least two hours after your last meal to avoid insulin-mediated GH suppression.
Recovery markers include improved sleep quality within 3–5 nights, reduced DOMS duration by 36–48 hours, elevated morning HRV, and 20–40% IGF-1 increase within 2–3 weeks.
Cycle the protocol. Use nightly for 5–7 days during acute recovery phases or 3–4 nights weekly for maintenance to prevent receptor desensitisation and preserve long-term efficacy.
What If: Recovery Protocol Scenarios
What If I Experience No Subjective Improvement After 7 Days?
First, verify injection timing and fasting compliance. Administering peptides within 90 minutes of a carbohydrate-rich meal blunts GH response by 40–50%. If timing is correct, assess baseline sleep quality: individuals with chronic sleep debt (averaging fewer than 6 hours nightly) often don't respond to GH secretagogues because cortisol dysregulation and insulin resistance suppress GH receptor sensitivity at the tissue level. Address sleep hygiene, magnesium intake (400–500mg glycinate form before bed), and eliminate blue-light exposure 60 minutes before injection. If no improvement after 14 days with corrected variables, consider baseline IGF-1 testing. Levels below 120 ng/mL may indicate pituitary insufficiency requiring clinical intervention beyond peptide use.
What If I Miss a Scheduled Injection During a Recovery Cycle?
Missing one injection won't negate the protocol's cumulative effect, but missing two or more within a 7-day cycle reduces overall GH exposure enough to delay recovery markers by 3–5 days. If you miss a dose, resume the protocol on the next scheduled night. Don't double-dose to compensate. Doubling CJC-1295 and Ipamorelin can cause transient hyperglycaemia and cortisol elevation as the body overcompensates for the exaggerated GH spike. Consistency matters more than perfection. Three properly timed injections per week produce better recovery outcomes than sporadic high-dose administration.
What If I Want to Combine CJC-1295 and Ipamorelin with Other Recovery Peptides?
CJC-1295 and Ipamorelin stack well with tissue-repair peptides like BPC-157 (body protection compound) or TB-500 (thymosin beta-4), which work through different mechanisms. BPC-157 upregulates VEGF (vascular endothelial growth factor) for angiogenesis, while TB-500 promotes actin polymerisation in damaged tissue. These can be injected simultaneously in separate syringes. Avoid combining with GHRP-6 or GHRP-2. Both are ghrelin mimetics like Ipamorelin but with higher cortisol and prolactin elevation, negating Ipamorelin's selectivity advantage. Never combine with exogenous growth hormone. The compounds work through endogenous secretion and will be suppressed entirely by synthetic GH.
The Clinical Truth About CJC-1295 and Ipamorelin for Recovery
Here's the honest answer: CJC-1295 no DAC and Ipamorelin are not magic. They don't override poor sleep, inadequate protein intake, or chronic overtraining. What they do. And do reliably. Is restore the hormonal environment your body needs to execute recovery processes that are already trying to happen but can't proceed efficiently due to suppressed GH output. If you're sleeping 4–5 hours a night, eating in a caloric deficit, and training six days a week without deload phases, no peptide will fix that. The protocol works when the foundation is in place: 7–8 hours of sleep, 1.6–2.2g protein per kilogram body weight daily, and structured training periodisation.
The evidence base is limited but consistent. A 2012 study published in Growth Hormone & IGF Research found that GHRH analogs (CJC-1295's category) increased IGF-1 levels by 47% over baseline in healthy adults after 28 days of use. Ipamorelin's selectivity for GHS-R1a receptors without cortisol or prolactin activation has been confirmed in multiple pharmacokinetic trials, making it the safest ghrelin mimetic for long-term use. What the research doesn't show: direct muscle hypertrophy from GH secretagogues alone. The anabolic effect is indirect. Through improved sleep, faster glycogen repletion, reduced systemic inflammation, and enhanced collagen synthesis in tendons and ligaments.
If your goal is muscle gain, you're better served by optimising training volume and nutritional periodisation. If your goal is faster recovery from high training loads or injury rehab, CJC-1295 and Ipamorelin are among the most effective, lowest-risk interventions available. Use them for what they do well. Don't expect them to compensate for what you're not doing elsewhere.
Our commitment to research-grade peptide quality extends across every compound we supply. If you're exploring recovery protocols that demand precision, reliability, and verifiable purity, explore our full peptide collection to see how small-batch synthesis and exact amino-acid sequencing support cutting-edge research.
The compounds work. But only when the protocol matches the biology. CJC-1295 no DAC and Ipamorelin don't replace sleep or nutrition, they amplify what those foundational inputs enable your body to do. Used correctly, they collapse recovery timelines and restore the hormonal rhythm that stress and aging erode. Used carelessly, they're expensive saline injections that produce no measurable benefit.
Frequently Asked Questions
Most users notice subjective sleep quality improvement within 3–5 nights of starting the protocol — deeper, less interrupted sleep is the first measurable effect. Quantitative recovery markers like reduced DOMS duration and improved morning HRV typically appear within 7–10 days. Serum IGF-1 elevation, which mediates most of the anabolic recovery effects, peaks after 2–3 weeks of consistent use at therapeutic doses.
No — combining GH secretagogues with exogenous growth hormone is counterproductive. Synthetic GH administration suppresses endogenous pulsatile secretion entirely through negative feedback at the hypothalamus and pituitary. CJC-1295 and Ipamorelin work by amplifying your body’s natural GH pulses — if those pulses are already shut down by exogenous GH, the peptides have no mechanism to act on.
CJC-1295 with DAC (drug affinity complex) has a half-life of 6–8 days and produces sustained GH elevation rather than pulsatile secretion, which can disrupt natural circadian rhythm and cause insulin resistance over time. CJC-1295 no DAC has a half-life of approximately 30 minutes to 2 hours, amplifying each natural GH pulse without creating continuous elevation — this preserves the ultradian rhythm and minimises metabolic side effects. For recovery protocols, no DAC is the superior choice.
Reconstituted peptides must be kept at 2–8°C to prevent degradation — room temperature storage denatures the peptide structure within 24–48 hours. Use an insulin travel cooler or FRIO wallet, which maintains refrigeration temperature for 36–48 hours without electricity. If traveling longer than two days, consider bringing lyophilised (unmixed) peptides and reconstituting on-site, as lyophilised powder tolerates ambient temperature for short periods without significant potency loss.
Recovery benefits are not permanent — they reflect the acute amplification of GH pulsatility while the peptides are active in your system. Once you stop, GH output returns to baseline within 48–72 hours, and recovery markers regress accordingly. However, the protocol doesn’t suppress endogenous GH production (unlike exogenous GH), so there’s no rebound suppression or ‘crash’ after discontinuation. You simply return to your natural baseline.
Both peptides are designed for subcutaneous injection and have not been studied extensively via intramuscular routes. Subcutaneous administration in the abdominal region provides slower, more sustained absorption and avoids the risk of hitting blood vessels or nerves present in deeper muscle tissue. There is no evidence that IM injection improves bioavailability or accelerates onset — stick with subcutaneous for safety and consistency.
The most common side effect is transient facial flushing or warmth within 10–15 minutes of injection, caused by histamine release — this resolves within 20–30 minutes and is harmless. Some users report mild water retention or joint stiffness during the first week, which typically subsides as the body adapts. Serious adverse effects are rare but include hypoglycaemia if injected on an empty stomach after intense training, and pituitary tumour risk in individuals with pre-existing pituitary abnormalities.
Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release without significantly elevating cortisol or prolactin — GHRP-6 and GHRP-2 also increase GH but cause cortisol spikes of 20–40% above baseline and prolactin elevation that can interfere with recovery and mood. Ipamorelin’s selectivity makes it safer for extended use in recovery protocols, particularly for individuals sensitive to cortisol dysregulation or those managing chronic stress.
Yes — growth hormone and IGF-1 both upregulate collagen synthesis and fibroblast proliferation, which are critical for tendon and ligament repair. Clinical evidence shows that GH secretagogues reduce healing time for soft tissue injuries by 15–30% when combined with appropriate load management and physical therapy. For targeted injury rehab, many researchers stack CJC-1295 and Ipamorelin with BPC-157, which works synergistically through VEGF upregulation and angiogenesis.
Elevated GH and IGF-1 increase muscle protein synthesis rates, but this effect is meaningless without adequate substrate availability. Aim for 1.6–2.2g protein per kilogram body weight daily, distributed across 4–5 meals to maintain leucine thresholds (2.5–3g per meal) that trigger mTOR activation. If protein intake is insufficient, the peptides will preferentially support glycogen repletion and immune function rather than muscle repair — you won’t see measurable recovery improvements.